---
title: "J.P. Morgan Reaffirms Their Hold Rating on Revvity (RVTY)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295233790.md"
description: "J.P. Morgan analyst Casey Woodring reaffirmed a Hold rating on Revvity (RVTY) with an $110 price target, following the stock's close at $114.24. This follows mixed sentiment from other analysts: Stifel Nicolaus also issued a Hold, while TD Cowen assigned a Buy rating to the healthcare company."
datetime: "2026-08-07T12:19:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295233790.md)
  - [en](https://longbridge.com/en/news/295233790.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295233790.md)
generator: "portal-rs"
---

# J.P. Morgan Reaffirms Their Hold Rating on Revvity (RVTY)

J.P. Morgan analyst Casey Woodring maintained a Hold rating on Revvity yesterday and set a price target of $110.00. The company’s shares closed yesterday at $114.24.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Woodring covers the Healthcare sector, focusing on stocks such as Icon, Illumina, and Guardant Health. According to TipRanks, Woodring has an average return of 3.7% and a 53.45% success rate on recommended stocks. 

In addition to J.P. Morgan, Revvity also received a Hold from Stifel Nicolaus’s Daniel Arias in a report issued on August 5. However, on the same day, TD Cowen assigned a Buy rating to Revvity (NYSE: RVTY).

### Related Stocks

- [RVTY.US](https://longbridge.com/en/quote/RVTY.US.md)
- [JPM.US](https://longbridge.com/en/quote/JPM.US.md)
- [ICLR.US](https://longbridge.com/en/quote/ICLR.US.md)
- [ILMN.US](https://longbridge.com/en/quote/ILMN.US.md)
- [GH.US](https://longbridge.com/en/quote/GH.US.md)
- [SF.US](https://longbridge.com/en/quote/SF.US.md)
- [TD.US](https://longbridge.com/en/quote/TD.US.md)
- [JPM-M.US](https://longbridge.com/en/quote/JPM-M.US.md)
- [JPM-C.US](https://longbridge.com/en/quote/JPM-C.US.md)
- [JPM-D.US](https://longbridge.com/en/quote/JPM-D.US.md)
- [JPM-L.US](https://longbridge.com/en/quote/JPM-L.US.md)
- [8634.JP](https://longbridge.com/en/quote/8634.JP.md)
- [JPM-K.US](https://longbridge.com/en/quote/JPM-K.US.md)
- [JPM-J.US](https://longbridge.com/en/quote/JPM-J.US.md)
- [SF-C.US](https://longbridge.com/en/quote/SF-C.US.md)
- [SFB.US](https://longbridge.com/en/quote/SFB.US.md)
- [SF-B.US](https://longbridge.com/en/quote/SF-B.US.md)
- [SF-D.US](https://longbridge.com/en/quote/SF-D.US.md)

## Related News & Research

- [Mitsubishi UFJ Asset Management Co. Ltd. Purchases Shares of 148,853 Revvity Inc. $RVTY](https://longbridge.com/en/news/296594343.md)
- [Major Insider Move at Globus Medical Shakes Up Investor Sentiment](https://longbridge.com/en/news/296439125.md)
- [J.P. Morgan Reaffirms Their Hold Rating on Pennantpark Investment (PNNT)](https://longbridge.com/en/news/296176376.md)
- [Canopy Growth publishes FY2026 annual report](https://longbridge.com/en/news/296603480.md)
- [BMO Capital Sticks to Their Buy Rating for Merck & Company (MRK)](https://longbridge.com/en/news/296482637.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**